FDA warns Glam Derma over website selling unapproved, misbranded injectable botulinum toxin products.
What happened
FDA reviewed www.glamderma.com and found it offered injectable botulinum toxin type A marketed as “NABOTA 100 Type A” and “Nabota 100” to U.S. consumers. Website claims included treating hyperhidrosis and blepharospasm, which FDA said showed the products are drugs intended for human use. FDA said there is no approved application for these products and their labeling lacks adequate directions for lay use.
What FDA found
The company offered an unapproved new drug, NABOTA 100 Type A/Nabota 100, for sale without an FDA-approved drug application.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]The product is a drug intended for human use based on website claims such as treating hyperhidrosis and blepharospasm.
FD&C Act section 201(g) [21 U.S.C. § 321(g)]The product is a new drug not generally recognized as safe and effective for its labeled uses.
FD&C Act section 201(p) [21 U.S.C. § 321(p)]The product’s labeling lacks adequate directions for use by a layperson.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]Offering the misbranded drug for sale to U.S. consumers causes it to be introduced into interstate commerce.
FD&C Act section 301(a) [21 U.S.C. § 331(a)]The prescription drug is not exempt from adequate-directions labeling because it is not approved in the U.S.
21 CFR 201.115(a)
What FDA wants
FDA asks Glam Derma to stop offering any unapproved and misbranded drugs to U.S. consumers and to notify FDA in writing within 15 working days of steps taken to correct violations and prevent recurrence.
Who should pay attention
- U.S. consumers who buy injectables online
- clinics or med spas considering unapproved botulinum toxin sources
- distributors and online sellers of imported drug products
This is a summary. Read the original letter on fda.gov.